Summary:

India’s pharmaceutical industry is expected to grow significantly, with exports projected to reach $350 billion by 2047, a 10-15x increase from current levels. As a global leader in generics, India aims to diversify into specialty generics, biosimilars, and innovative pharmaceuticals. The focus will shift from a volume-based to a value-driven approach, particularly in APIs, biosimilars, and generic formulations, ensuring long-term growth.

A Bain & Company report highlights key growth areas, including API exports, expected to rise from $5 billion to $80-90 billion by 2047, and biosimilar exports, projected to expand fivefold to $30-35 billion. Generic formulations, the largest export segment, are anticipated to reach $180-190 billion, with a strong focus on specialty generics. The report emphasizes the importance of policy initiatives, R&D, government-private partnerships, and investments in CDMOs and CROs to drive industry growth.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.